Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,030.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by TD Cowen from $1,020.00 to $1,030.00 in a research report sent to investors on Wednesday morning, Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on the company. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a report on Wednesday, March 13th. StockNews.com downgraded Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Saturday, April 20th. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an outperform rating in a report on Monday, February 5th. Barclays lifted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an overweight rating in a report on Tuesday, January 23rd. Finally, Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an outperform rating and a $1,125.00 price target for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $977.77.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $883.20 on Wednesday. The firm has a 50-day moving average of $948.00 and a two-hundred day moving average of $894.04. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The stock has a market cap of $96.94 billion, a P/E ratio of 25.42, a PEG ratio of 2.56 and a beta of 0.11. Regeneron Pharmaceuticals has a 1-year low of $684.80 and a 1-year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the previous year, the firm posted $10.96 earnings per share. The company’s revenue was up .6% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals will post 38.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of REGN. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $26,000. West Paces Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. MCF Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.